TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21118924

Group type: EXPERIMENTAL
Intervention: Monthly SP
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: AZI-SP (monthly SP and two doses of azithromycin)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Controls (sulfadoxine‐pyrimethamine twice)
Number of subjects: 1320
Study: 17541591

Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 i.v.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vinorelbine 80 mg/m2 oral
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both oral and i.v. forms
Number of subjects: 48
Study: 15821961

Group type: EXPERIMENTAL
Intervention: 3D‐SSP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thin‐section MR imaging
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transaxial SPECT display
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Perfusion MR imaging
Number of subjects: 66
Study: 11956002

Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9585289

Group type: COMPARATOR
Intervention: Lidocaine without epinephrine (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.2 mg of epinephrine (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.4 mg of epinephrine (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.6 mg of epinephrine (Group D)
Number of subjects: 80
Study: 7712756

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.1 mg/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2667704

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (52 mg/nasal cavity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (topically applied)
Number of subjects: 12
Study: 827772

Group type: EXPERIMENTAL
Intervention: Physostigmine (3 mg total dose, intravenously)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (0.25 N saline, intravenously)
Number of subjects: 23
Study: 31059560

Group type: EXPERIMENTAL
Intervention: 54 primer pairs selected for polymorphism validation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polymorphic EST-SSR markers
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cross-transferability of markers
Number of subjects: 96
Study: 28088688

Group type: EXPERIMENTAL
Intervention: CAPOX and bevacizumab (arm A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: CAPOX alone (arm B)
Number of subjects: 79
Study: 26631990

Group type: EXPERIMENTAL
Intervention: Intramedullary device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extramedullary hip screw
Number of subjects: 0
Study: 23749226

Group type: EXPERIMENTAL
Intervention: Protocol A (100 kVp, 370 mgI/kg over 15 s)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Protocol B (100 kVp, 296 mgI/kg over 10 s)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Protocol C (80 kVp, 296 mgI/kg over 10 s)
Number of subjects: 98
Study: 22043678

Group type: EXPERIMENTAL
Intervention: Acupuncture based on syndrome differentiation combined with pricking and cupping
Number of subjects: 86

Group type: COMPARATOR
Intervention: Simple pricking and cupping
Number of subjects: 86
Study: 18613931

Group type: EXPERIMENTAL
Intervention: i.v. dexmedetomidine 1‐4 mug.kg(‐1) bolus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Simulation of an infusion of 1 mug.kg(‐1) over 10 min followed by an infusion of 0.7 mug.kg(‐1).h(‐1) for 50 min
Number of subjects: 45
Study: 15760322

Group type: EXPERIMENTAL
Intervention: Weekly intramuscular methotrexate at 30 mg/m(2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks
Number of subjects: 46
Study: 11896345

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs
Number of subjects: 531

Group type: COMPARATOR
Intervention: Unmodified RBCs
Number of subjects: 531
Study: 10567783

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg o.d. for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.d. for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg o.d. for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7602635

Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metal staples
Number of subjects: 20
Study: 2924604

Group type: EXPERIMENTAL
Intervention: 30 percent oxygen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Air
Number of subjects: 17
Study: 387068

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 40 mg by mouth daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31186299

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 28108873

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Employment hope
Number of subjects: 103

Group type: COMPARATOR
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Exposure to community violence (ECV)
Number of subjects: 103
Study: 26292916

Group type: EXPERIMENTAL
Intervention: Adaptive tutorials
Number of subjects: 99

Group type: COMPARATOR
Intervention: Web resource (Control)
Number of subjects: 99
Study: 23944300

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 16 weeks (TID16W)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 28 weeks (TID28W)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 40 weeks (TID40W)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg twice daily plus ribavirin for 28 weeks (BID28W)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily without ribavirin for 28 weeks (TID28W‐NR)
Number of subjects: 362

Group type: COMPARATOR
Intervention: TID28W
Number of subjects: 362
Study: 21740578

Group type: EXPERIMENTAL
Intervention: Intramuscular diamorphine
Number of subjects: 406

Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 406
Study: 18829025

Group type: EXPERIMENTAL
Intervention: Electroactivation of oocytes (n = 1,640)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (no electroactivation, n = 1,435)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study: 16223550

Group type: EXPERIMENTAL
Intervention: CHAT gene intron 9 SNP
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Three-site haplotype analysis of intron 9 SNP
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: CHAT SNPs
Number of subjects: 1709
Study: 15291378

Group type: EXPERIMENTAL
Intervention: Olmesartan 10 mg/d
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/d
Number of subjects: 1547
Study: 11997274

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/d)
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Both n-3 PUFAs and Vitamin E
Number of subjects: 11323

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11323
Study: 9457003

Group type: EXPERIMENTAL
Intervention: Saliva sample request with incentives (lottery, pen)
Number of subjects: 2994

Group type: COMPARATOR
Intervention: Control group (no saliva sample request)
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Lottery incentive
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Pen incentive
Number of subjects: 2994
Study: 8903980

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 32
Study: 2093382

Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg per day
Number of subjects: 20
Study: 342437

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 79
Study: 29571969

Group type: EXPERIMENTAL
Intervention: Anterior myotomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Posterior myotomy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups (anterior and posterior myotomy)
Number of subjects: 63
Study: 26718414

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: HF-DASH diet
Number of subjects: 36
Study: 24020868

Group type: EXPERIMENTAL
Intervention: Informed innocents with promised reward
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Guilty participants with promised reward
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Informed innocents without promised reward
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Guilty participants without promised reward
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (uninformed innocents)
Number of subjects: 100
Study: 24261811

Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with a minimum immunizing dose of BRSV (experiment 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with a commercially available combination modified-live virus vaccine (experiments 2 and 3)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intranasal vaccination (experiments 1, 2, and 3)
Number of subjects: 84
Study: 20100020

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 385

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Overall AQLQ score
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Emotion domain of AQLQ
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Symptoms domain of AQLQ
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Enrollment AQLQ scores
Number of subjects: 385
Study: 17551835

Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate (BBIC) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17242499

Group type: EXPERIMENTAL
Intervention: Oral prednisone, 40 mg/day for 7 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intramuscular triamcinolone LA, 40 mg/day for 3 days
Number of subjects: 88
Study: 12540390

Group type: EXPERIMENTAL
Intervention: L. helveticus LBK‐16H fermented milk (150 mL/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 39
Study: 10837004

Group type: EXPERIMENTAL
Intervention: Brassica vegetable diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Apiaceous vegetable diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Basal (vegetable‐free) diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Allium vegetable diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NAT2 and xanthine oxidase activities
Number of subjects: 36
Study: 8861533

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily intravenously for 2-4 days followed by oral doses of 400 mg for up to 10 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg twice daily intravenously for 2-4 days followed by oral doses of 2 x 500 mg for up to 10 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 93
Study: 1814749

Group type: EXPERIMENTAL
Intervention: Afferent tubular isoperistaltic ileal segment (20-cm length)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antireflux nipple
Number of subjects: 60
Study: 6366124

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (C‐MOPP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 150
Study: 31310989

Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 41
Study: 28254107

Group type: EXPERIMENTAL
Intervention: Acupuncture to a myofascial trigger point (MTrP) in the upper trapezius
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture to the MTrP in addition to relevant distal points
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture to the relevant distal points only
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham treatment to both the MTrP and distal points using a deactivated acupuncture laser device
Number of subjects: 80
Study: 25790807

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-diuretic antihypertensive drugs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 23782796

Group type: EXPERIMENTAL
Intervention: mobiletype program (intervention group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: attention-comparison group (control)
Number of subjects: 114
Study: 21752280

Group type: EXPERIMENTAL
Intervention: ICT guided disease management + Telemonitoring (DM+TM)
Number of subjects: 220

Group type: COMPARATOR
Intervention: ICT guided disease management (DM)
Number of subjects: 220
Study: 19205490

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (proxymetacaine eye drops)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia (2% xylocaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia (2% xylocaine)
Number of subjects: 60
Study: 16798995

Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 31

Group type: COMPARATOR
Intervention: Mayo resection
Number of subjects: 31
Study: 15307520

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC‐‐Migpriv)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ergotamine plus caffeine (2 mg ERG + 200 mg CAF‐‐Coffecorn forte)
Number of subjects: 98
Study: 10927062

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic ovarian drilling under local anesthesia and conscious sedation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional ovarian drilling by laparoscopy under general anesthesia
Number of subjects: 62
Study: 9709274

Group type: EXPERIMENTAL
Intervention: Mammographic screening (invited women aged 40-49)
Number of subjects: 2468

Group type: EXPERIMENTAL
Intervention: Mammographic screening (invited women aged 50-74)
Number of subjects: 2468

Group type: EXPERIMENTAL
Intervention: Poorly differentiated (grade 3) ductal carcinoma (invited women aged 40-49)
Number of subjects: 2468
Study: 8310757

Group type: EXPERIMENTAL
Intervention: Schedule A (two doses at day 0, one dose at day 21)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Schedule B (one dose at days 0, 10 and 21)
Number of subjects: 89
Study: 2874755

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (no prophylactic therapy)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sotalol (for termination of SVT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Metoprolol (for termination of SVT)
Number of subjects: 130
Study: 30946210

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg twice a day for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intranasal steroid (mometasone furoate nasal spray for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both groups (Erythromycin and Intranasal steroid)
Number of subjects: 72
Study: 28944218

Group type: EXPERIMENTAL
Intervention: Self-reported comorbidities (including diabetes)
Number of subjects: 7540

Group type: EXPERIMENTAL
Intervention: Self-reported SMCs
Number of subjects: 7540
Study: 25791214

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study: 23995774

Group type: EXPERIMENTAL
Intervention: Cocaine vaccine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 21185661

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study: 19272639

Group type: EXPERIMENTAL
Intervention: ERBB2 amplification defined as >2 copies of ERBB2/CEP17
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ERBB2 amplification defined as >4 copies of ERBB2/nuclei
Number of subjects: 133
Study: 16572918

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg (test formulation)
Number of subjects: 24
Study: 12511311

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg
Number of subjects: 105
Study: 12174784

Group type: EXPERIMENTAL
Intervention: Heat application (whole-body hot shower)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Parenteral analgesics or tranquillizers
Number of subjects: 113
Study: 9850348

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 micrograms twice daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 23
Study: 8120720

Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 79
Study: 2531051

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol nebulizer solutions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoterol nebulizer solution
Number of subjects: 0
Study: 788000

Group type: EXPERIMENTAL
Intervention: Noxiptilin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 62
Study: 31311460

Group type: EXPERIMENTAL
Intervention: Condition with doubt
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 650
Study: 28008098

Group type: EXPERIMENTAL
Intervention: 3 pmol·kg−1·min−1 BNP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26004151

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid (GS) treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 48
Study: 23859438

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exposure to program sections
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 53
Study: 21366172

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19273705

Group type: EXPERIMENTAL
Intervention: Thalidomide consolidation therapy for 12 months
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group with indefinite prednisolone maintenance therapy
Number of subjects: 269
Study: 17327603

Group type: EXPERIMENTAL
Intervention: Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols
Number of subjects: 844
Study: 15546820

Group type: EXPERIMENTAL
Intervention: Methylene blue (16 patients)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isosulfan blue (16 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (6 patients, no dyes used)
Number of subjects: 32
Study: 11871585

Group type: EXPERIMENTAL
Intervention: Nurse-administered self-efficacy intervention given on five monthly occasions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 9924367

Group type: EXPERIMENTAL
Intervention: Dorzolamide (topical carbonic anhydrase inhibitor, three times daily, one eye)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (vehicle treatment)
Number of subjects: 33
Study: 8000692

Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 14
Study: 30206918

Group type: EXPERIMENTAL
Intervention: Wheelchair skills training (n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional exercise sessions (n=11)
Number of subjects: 24
Study: 26827067

Group type: EXPERIMENTAL
Intervention: Tapered MIS® Seven implants (TI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cylindrical Astra® Osseospeed implants (CI)
Number of subjects: 47
Study: 24866311

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment strategy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Advice on diet and exercise (Control)
Number of subjects: 115
Study: 22960434

Group type: EXPERIMENTAL
Intervention: Armodafinil (250 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 34
Study: 20222840

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day plus r-FSH (37.5 units/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Myo-inositol (4 g) plus folic acid (400 microg) daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid plus r-FSH (37.5 units/day)
Number of subjects: 120
Study: 18258384

Group type: EXPERIMENTAL
Intervention: Concomitant temozolomide (TMZ) at 50 mg/m² (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Concomitant temozolomide (TMZ) at 75 mg/m² (Group B)
Number of subjects: 160
Study: 15920447

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 2 g amoxicillin 1 hour before every appointment (n=23)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment (control group, n=24)
Number of subjects: 39
Study: 12829663

Group type: EXPERIMENTAL
Intervention: 12 cycles of single-agent paclitaxel administered every 28 days
Number of subjects: 277

Group type: COMPARATOR
Intervention: 3 cycles of single-agent paclitaxel administered every 28 days
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 277